For the first quarter of 2009, the company reported net sales of $12.47 million, compared to $11.49 million for the same quarter in 2008.
Ron Cohen, president and CEO of Acorda Therapeutics, said: “I am pleased that we were able to work quickly to address the comments from the FDA and resubmit our new drug application (NDA), approximately three weeks from having received the refuse to file letter on our initial NDA submission, and that the FDA accepted the filing two weeks later.
“We are also encouraged that the FDA has elected to assign priority review status to the Fampridine-SR NDA. Our focus in the coming months is to work with the FDA during the regulatory review of Fampridine-SR, to prepare for its launch in the US, if approved, and to continue discussions with potential Fampridine-SR commercialization partners for ex-US markets.”